Eli Lilly's Symbyax is for the treatment of treatment-resistant depression and bipolar I depression in adults.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has launched its generic version of Symbyax, Eli Lilly & Co's (NYSE: LLY) treatment for treatment-resistant depression and bipolar I depression in adults. Brand Symbyax has $82 million in annual US sales, based on IMS sales data.
Teva is launching Olanzapine and Fluoxetine capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg.
Teva's share price rose 8.8% to NIS 158.80 in morning trading on the TASE today, after rising 0.7% on Nasdaq yesterday to $38.01, giving a market cap of $33.1 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on June 24, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012